---
title: "NeuroSense Therapeutics - Unit (NRSN.US) — Financial Reports"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/NRSN.US/norm.md"
symbol: "NRSN.US"
name: "NeuroSense Therapeutics - Unit"
parent: "https://longbridge.com/en/quote/NRSN.US.md"
datetime: "2026-03-09T11:25:33.734Z"
locales:
  - [en](https://longbridge.com/en/quote/NRSN.US/norm.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/NRSN.US/norm.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/NRSN.US/norm.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/NRSN.US/norm.md) | [繁體中文](https://longbridge.com/zh-HK/quote/NRSN.US/norm.md)


# NeuroSense Therapeutics - Unit (NRSN.US) — Financial Reports

## Income Statement (USD)

| Indicator | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
| --- | --- | --- | --- | --- | --- |
| EPS | -0.0927 | -0.0927 | -0.0832 | -0.1118 | -0.0472 |
| ROE | 1814.64% | -912.60% | 6131.06% | 380.09% | 78.84% |
| Revenue | - | - | - | - | - |
| Net income | -2.35M | -2.35M | -1.80M | -2.15M | -857000.00 |
| Operating income | -2.35M | -2.35M | -1.77M | -2.11M | -3.03M |
| Gross margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| Profit quality | - | - | - | - | - |

## Balance Sheet (USD)

| Indicator | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
| --- | --- | --- | --- | --- | --- |
| A&L | 1.68M | 1.68M | 4.58M | 984000.00 | 1.84M |
| Leverage | -3.24 | -3.24 | 1.77 | -0.3492 | -1.08 |
| BVPS | -0.0211 | -0.0211 | 0.1112 | -0.1423 | -0.0943 |
| Turnover | - | - | - | - | - |
| Cash & STI | 666000.00 | 666000.00 | 3.38M | 344000.00 | 1.21M |
| Inv & Rec | - | - | 738000.00 | - | - |
| LT assets | 105000.00 | 105000.00 | 150000.00 | 176000.00 | 200000.00 |
| Net debt | -666000.00 | -666000.00 | -3.31M | -325000.00 | -1.17M |

## Cash Flow Statement (USD)

| Indicator | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
| --- | --- | --- | --- | --- | --- |
| Operating CF | -2.00M | -2.00M | - | - | - |
| Investing CF | -6500.00 | -6500.00 | - | - | - |
| Financing CF | 650500.00 | 650500.00 | - | - | - |
| Free CF | -1.31M | -893750.00 | - | - | - |
| OCF coverage | -80000.00% | -80000.00% | - | - | - |
| Repaid & issued | - | - | - | - | - |
| CapEx | -2500.00 | -2500.00 | - | - | - |